Harmonic Discovery

What do you get when you mix life science #startups and investors with an informal setting and a relaxed environment? NOME Investor Day 2024! ?? Thank you to everyone who attended this year's investor day. From startups to investors and even mentors, who came from far and wide to participate ?? The NOME community wouldn't be this strong without your commitment to making it the best there is. The buzz around the tables seemed to indicate that there was plenty to talk about, although we have to agree that when the bell rings, you have no more time ?? We truly hope to see many of you again very soon!

?? Meet the BIO-Europe? 2024 Startup Spotlight finalists! With over 60 submissions from the most dynamic biotech startups, selecting just 8 finalists was quite a challenge. This is your opportunity to hear directly from the finalists as they showcase their innovations and discuss the visions that hold the potential to reshape the future of healthcare! Don't miss out on this thrilling competition, register for Bio-Europe today and save €600 on your pass >> https://lnkd.in/gSmS3EBb Thank you to Bayer Co.Lab for sponsoring the Startup Spotlight. #BIOEurope #biotech #StartupSpotlight #Innovation #Entrepreneur

Excited to share our paper published in Nature Communications led by Ryan Theisen and Anna Cichonska! In the paper we describe a novel machine learning methodology that's set to transform bioactivity data use in early-stage drug discovery. Our method maximizes the use of bioactivity data, including historically overlooked types, to significantly boost drug activity prediction accuracy. This advancement not only expands the chemical space we can confidently explore but also brings a new level of efficiency and cost-effectiveness to training data preparation. You can find a summary and related commentary here: https://lnkd.in/e7-xgYPn Paper link ?? : https://lnkd.in/ekvmvjqx Code link ??: https://lnkd.in/ekmb6NhE

Excited to share our paper published in Nature Communications led by Ryan Theisen and Anna Cichonska! In the paper we describe a novel machine learning methodology that's set to transform bioactivity data use in early-stage drug discovery. Our method maximizes the use of bioactivity data, including historically overlooked types, to significantly boost drug activity prediction accuracy. This advancement not only expands the chemical space we can confidently explore but also brings a new level of efficiency and cost-effectiveness to training data preparation. You can find a summary and related commentary here: https://lnkd.in/e7-xgYPn Paper link ?? : https://lnkd.in/ekvmvjqx Code link ??: https://lnkd.in/ekmb6NhE

Excited to share our paper published in Nature Communications led by Ryan Theisen and Anna Cichonska! In the paper we describe a novel machine learning methodology that's set to transform bioactivity data use in early-stage drug discovery. Our method maximizes the use of bioactivity data, including historically overlooked types, to significantly boost drug activity prediction accuracy. This advancement not only expands the chemical space we can confidently explore but also brings a new level of efficiency and cost-effectiveness to training data preparation. You can find a summary and related commentary here: https://lnkd.in/e7-xgYPn Paper link ?? : https://lnkd.in/ekvmvjqx Code link ??: https://lnkd.in/ekmb6NhE

I truly appreciated the opportunity to speak at the Biden Cancer Moonshot Workshop: Using AI Approaches to Target Undruggable Cancer Targets in Washington, DC. It was a great event filled with insightful discussions on the latest advancements in AI, structural biology, and systems approaches to tackling some of the most challenging cancer targets. Thank you for the invitation, Olivier Elemento, Regina Barzilay, and Sean Hanlon! #CancerMoonshot

Join us at The Colorado Convention Center for #ACSFall2024 where 3 of the Harmonic Discovery team members will be presenting. On Sunday, August 18, 2024, at 10:15, Navriti Sahni, PhD will give her presentation, Cmp-CGM: Chemotype Annotation, Screening, and Discovery of Compounds through a Coarse Grain Model based on Reduced Graph Representations, at Bluebird Ballroom 2H. On Tuesday, August 20, 2024, both Ryan Theisen, PhD, and Francesco Trozzi, PhD, will be presenting separately in Room 705. Catch Ryan’s presentation, Unveiling the Core Components of Success in Drug-target Interaction Modeling: A Systematic Study, at 8:20 AM, and Francesco’s presentation, Steering Colabfold Kinase Structures Generation to Discover Novel State-Specific Inhibitors Across the Kinome, at 11:00 AM. We hope to see you there!

We are thrilled to share that Harmonic Discovery was selected as the winner for the inaugural JP Morgan Asset Management Life Sciences Innovation Summit in Abu Dhabi! We would like to thank J.P. Morgan Asset Management Life Science Private Capital, Blue Horizon Advisors, Lyfebulb, the Department of Health Abu Dhabi, and the judges for hosting and organizing the summit. It was an honor to present Harmonic Discovery and our technology, and we are excited to develop novel therapeutics and support the life science ecosystem in the Emirati region. https://lnkd.in/e6hsjQd3

We're throwing a panel discussion with networking on Leveraging Gen AI for Drug Discovery on June 7th at 5pm. We are co-hosting with our friends over at Kaleidoscope.bio, Amazon Web Services (AWS), Gunderson Dettmer and a16z Tech Week at Biolabs@NYULangone for #Techweek NYC We have an awesome panel of speakers from biotech, industry and VC! Register here: https://lu.ma/tx1tr61x #TechWeek

Taking place on the sidelines of Abu Dhabi Global Healthcare Week (ADGHW), hosted by the Department of Health Abu Dhabi– Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, J.P. Morgan Asset Management’s Life Sciences Private Capital, Blue Horizon Advisors and United AlSaqer Group announce the 11 finalists of the inaugural Life Sciences Innovation Summit 2024 on May 14 – 15, 2024. Finalists selected to compete in the summit include: Algen Biotechnologies, Chun-Hao Huang, PhD, Co-Founder & CEO AnaCardio, Patrik Str?mberg, PhD, CEO Chimera Therapeutics, Matthew Lorence, PhD, Co-Founder & CEO Harmonic Discovery, Rayees R., PhD, CEO Lactocore Group, Anton Malyshev, PhD, Founder & CEO Medicovestor, Inc., Seah Lim, PhD, CEO Oncoheroes Biosciences, Cesare Spadoni, PhD, Co-Founder & Chief Operating Officer Paradox Immunotherapeutics, Natalie J. Galant, PhD, PhD, Co-Founder & CEO SaudiVax, Mazen Hassanain MD, PhD, FACS, PhD, CEO Ypsilon Therapeutics, Dongxing Zha, PhD, Founder & CEO ZTI BIOSCIENCES, Jaden Hyungseok C., PhD, CEO Stephen Squinto, PhD, Chief Investment Officer, J.P. Morgan Life Sciences Private Capital said: “We are very pleased to be partnering with the stellar leadership of the Department of Health – Abu Dhabi, Blue Horizon Advisors, United AlSaqer Group, Cleveland Clinic Abu Dhabi and other local leaders in launching our inaugural innovation summit.” Nabil Kobeissi, Chief Executive Officer, Blue Horizon Advisors added: “We are grateful to these preeminent scientists and business leaders for coming to Abu Dhabi to experience our growing innovation hub and meet these stellar finalists. With over 150 highly qualified applications submitted from around the globe, clearly the medical research and innovation community is paying attention to this event.” The finalists will be judged by an esteemed panel, which includes: Laurie Glimcher, MD, President and CEO at Dana-Farber Cancer Institute Jorge A. Guzman, MD, MBA, MD, CEO at Cleveland Clinic Abu Dhabi Prof. Shahrukh Khurshid Hashmi, Director of Research at Department of Health, Abu Dhabi David Hung, M.D., MD, Founder, President and CEO at Nuvation Bio Yasmine Hayek Kobeissi Ph.D, PhD, CQF, BSc., Executive Director at Blue Horizon Advisors Anya Schiess, Managing Partner at J.P. Morgan Life Sciences Private Capital Click Here: https://lnkd.in/dh6ESWYD #adghw #mededgemea #abudhabi #dohabudhabi #uae J.P. Morgan